Summary
McKesson Corporation reported an increase in revenues for the third quarter and first nine months of fiscal year 2024, driven by strong performance in its U.S. Pharmaceutical segment, particularly in specialty pharmaceuticals and retail national accounts. Despite revenue growth, gross profit saw a slight decrease due to the impact of the European divestiture and increased operating expenses. Diluted earnings per share from continuing operations experienced a significant decline year-over-year, largely influenced by a substantial provision for bad debts related to the bankruptcy of its customer, Rite Aid. The company's financial position remains solid, with active capital allocation strategies including significant share repurchases and dividend payments. McKesson is managing its debt effectively and has a substantial remaining authorization for stock buybacks. However, investors should note the ongoing legal proceedings, particularly those related to opioid litigation, which represent a significant contingent liability. The company continues to navigate these challenges while focusing on operational efficiencies and strategic growth.
Financial Highlights
53 data points| Revenue | $80.90B |
| Cost of Revenue | $77.75B |
| Gross Profit | $3.15B |
| SG&A Expenses | $2.51B |
| Operating Expenses | $2.51B |
| Operating Income | $642.00M |
| Interest Expense | $64.00M |
| Net Income | $589.00M |
| EPS (Basic) | $4.45 |
| EPS (Diluted) | $4.42 |
| Shares Outstanding (Basic) | 132.50M |
| Shares Outstanding (Diluted) | 133.30M |
Key Highlights
- 1Revenues increased by 15% for the three months ended December 31, 2023, and by 12% for the nine months ended December 31, 2023, driven by the U.S. Pharmaceutical segment.
- 2Diluted earnings per share from continuing operations attributable to McKesson Corporation decreased significantly to $4.42 from $7.65 year-over-year for the three-month period.
- 3A substantial provision for bad debts of $515 million and $725 million was recorded for the three and nine months ended December 31, 2023, respectively, due to the bankruptcy of customer Rite Aid.
- 4Gross profit decreased by 1% for both the three and nine-month periods, impacted by the divestiture of European businesses and increased operating expenses.
- 5The company returned approximately $2.6 billion to shareholders in the first nine months of fiscal year 2024 through share repurchases and dividends, with a remaining authorization of $7.3 billion for stock buybacks.
- 6McKesson's total estimated liability for opioid-related claims stood at $6.6 billion as of December 31, 2023, with $516 million classified as current.
- 7Operating expenses increased by 30% for the three-month period and 11% for the nine-month period, primarily due to the provision for bad debts.